Showing 9771-9780 of 20328 results for "".
- Localized IL-15 Immunotherapy with a Delayed-Release Implant for Glioblastomahttps://reachmd.com/news/il-15-immunotherapy-implant-glioblastoma/2485586/A multidisciplinary team at the University of Cincinnati is developing an implantable,
- IMCAS 2026: Galderma Survey Sheds Light on Menopause and Skin Healthhttps://reachmd.com/news/imcas-2026-galderma-survey-sheds-light-on-menopause-and-skin-health/2485587/Galderma presented findings from a large global survey examining the dermatologic impact of menopause at the International Master Course on Aging Science (IMCAS) 2026 World Congress, held January 29–31 in Paris, France. The survey notes persistent gaps in awareness and education around menopause-
- Vitamin D Linked to Shifts in Non-Coding RNA Networks During Zika Virus Infection in Human Macrophageshttps://reachmd.com/news/vitamin-d-linked-to-shifts-in-non-coding-rna-networks-during-zika-virus-infection-in-human-macrophages/2485571/A new exploratory transcriptomic study suggests that vitamin D conditioning is associated with broad shifts in non-coding RNA expression and predicted regulatory networks in human macrophages infected with Zika virus, highlighting candidate lnc
- Epigenetic Instability and Liquid Biopsy: Rethinking Early Cancer Detectionhttps://reachmd.com/news/epigenetic-instability-liquid-biopsy-cancer-detection/2485576/Johns Hopkins investigators describe a liquid-biopsy early-detection framework that emphasizes ep
- Rising Rates of Psychosis in Younger Generations: A Clinical and Service Implication Reviewhttps://reachmd.com/news/rising-rates-of-psychosis-in-younger-generations-a-clinical-and-service-implication-review/2485547/A recent study in Ontario shows a sharp rise in new psychosis diagnoses among younger birth cohorts — a finding with immediate implications for early intervention and service-capacity planning. Ne
- Microbiome-Targeted Approaches in Post-Infectious IBS: A Pilot Study Reviewhttps://reachmd.com/news/microbiome-targeted-approaches-in-post-infectious-ibs-a-pilot-study-review/2485545/Targeted microbiome modulation produced clinically meaningful benefit in a pilot case–control study for post-infectious irritable bowel syndrome (PI-IBS), showin
- New Compounds Identified for ROS1 G2032R Mutationhttps://reachmd.com/news/new-compounds-identified-for-ros1-g2032r-mutation/2485501/A recent computational study has identified four small molecules that may inhibit the crizotinib-resistant ROS1 G2032R mutation found in non-small-cell lung cancer (NSCLC). Resistance to ROS1-targeted therapies,
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://reachmd.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://reachmd.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://reachmd.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame